The Divergent Cardiovascular Effects of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers on Myocardial Infarction and Death

Progress in Cardiovascular Diseases

Volumn 58, Issue 5, 2016, Pages 473-482

  Strauss, Martin H ^a   Hall, Alistair S ^b  

^a NORTH YORK GENERAL HOSPITAL   (Canada)

^b LEEDS GENERAL INFIRMARY   (United Kingdom)

Author keywords

ACEi meta analysis; Angiotensin converting enzyme inhibitor (ACEi); Angiotensin II AT1 receptor blocker (ARB); ARB meta analysis; Death; Meta regression analysis; Myocardial infarction (MI); Renin angiotensin aldosterone system (RAAS); Stroke (CVA)

Indexed keywords

AMLODIPINE; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; BRADYKININ; CANDESARTAN; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; LOSARTAN; OLMESARTAN; PLACEBO; RAMIPRIL; TELMISARTAN; VALSARTAN;

CARDIOVASCULAR EFFECT; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CONGESTIVE HEART FAILURE; DEATH; DIABETES MELLITUS; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; END STAGE RENAL DISEASE; HEART FAILURE; HEART INFARCTION; HEART PROTECTION; HIGH RISK PATIENT; HORMONE RECEPTOR INTERACTION; HUMAN; HYPERTENSION; MORTALITY; PRACTICE GUIDELINE; RENAL PROTECTION; REVIEW; RISK REDUCTION; VASCULAR DISEASE; BLOOD PRESSURE; COMORBIDITY; DRUG EFFECTS; MYOCARDIAL INFARCTION; PATHOPHYSIOLOGY; PATIENT SELECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK ASSESSMENT; RISK FACTOR; TREATMENT OUTCOME;

ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BLOOD PRESSURE; COMORBIDITY; HUMANS; HYPERTENSION; MYOCARDIAL INFARCTION; PATIENT SELECTION; RENIN-ANGIOTENSIN SYSTEM; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 84949657243     PISSN: 00330620     EISSN: 18731740     Source Type: Journal    
DOI: 10.1016/j.pcad.2015.11.004     Document Type: Review

References (56)

1. Blood pressure-dependent and independent effects of agents that inhibit the renin-angiotensin system. J Hypertens 2007, 25(5):951-958.
2. Sarafidis P.A., Stafylas P.C., Kanaki A.I., Lasaridis A.N. Effects of renin-angiotensin system blockers on renal outcomes and all-cause mortality in patients with diabetic nephropathy: an updated meta-analysis. Am J Hypertens 2008, 21(8):922-929.
3. Pfeffer M.A., McMurray J.J., Velazquez E.J., et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003, 349(20):1893-1906.
4. Strauss M.H., Hall A.S. Angiotensin receptor blockers may increase risk of myocardial infarction: unraveling the ARB-MI paradox. Circulation 2006, 114(8):838-854.
5. Daskalopoulou S.S., Khan N.A., Quinn R.R., et al. The 2012 Canadian hypertension education program recommendations for the management of hypertension: blood pressure measurement, diagnosis, assessment of risk, and therapy. Can J Cardiol 2012, 28(3):270-287.
6. American Diabetes Association Standards of medical care - 2013. Diabetes Care 2013, S11-S56.
7. Mancia G., Fagard R., Narkiewicz K., et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2013, 34(28):2159-2219.
8. Savarese G., Costanzo P., Cleland J.G., et al. A meta-analysis reporting effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients without heart failure. J Am Coll Cardiol 2013, 61(2):131-142.
9. Bangalore S., Kumar S., Wetterslev J., Messerli F.H. Angiotensin receptor blockers and risk of myocardial infarction: meta-analyses and trial sequential analyses of 147 020 patients from randomised trials. BMJ 2011, 342:d2234.
10. Elgendy I.Y., Huo T., Chik V., Pepine C.J., Bavry A.A. Efficacy and safety of angiotensin receptor blockers in older patients: a meta-analysis of randomized trials. Am J Hypertens 2015, 28(5):576-585.
11. Verdecchia P., Reboldi G., Angeli F., et al. Angiotensin-converting enzyme inhibitors and calcium channel blockers for coronary heart disease and stroke prevention. Hypertension 2005, 46(2):386-392.
12. Lewington S., Clarke R., Qizilbash N., Peto R., Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002, 360(9349):1903-1913.
13. Law M.R., Morris J.K., Wald N.J. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009, 338:b1665.
14. van Vark L.C., Bertrand M., Akkerhuis K.M., et al. Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158 998 patients. Eur Heart J 2012, 33(16):2088-2097.
15. Verma S., Strauss M. Angiotensin receptor blockers and myocardial infarction. BMJ 2004, 329(7477):1248-1249.
16. Julius S., Kjeldsen S.E., Weber M., et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004, 363(9426):2022-2031.
17. Granger C.B., McMurray J.J., Yusuf S., et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003, 362(9386):772-776.
18. Sever P.S., Poulter N.R., Elliott W.J., et al. Blood pressure reduction is not the only determinant of outcome. Circulation 2006, 113(23):2754-2772.
19. Tsuyuki R.T., McDonald M.A. Angiotensin receptor blockers do not increase risk of myocardial infarction. Circulation 2006, 114(8):855-860.
20. Volpe M., Tocci G., Sciarretta S., Verdecchia P., Trimarco B., Mancia G. Angiotensin II receptor blockers and myocardial infarction: an updated analysis of randomized clinical trials. J Hypertens 2009, 27(5):941-946.
21. Macia-Heras M, Castillo-Rodrigues N, Gonzalez J. The renin-angiotensin-aldosterone system in renal and cardiovascular disease and the effects of its pharmacological blockade. J Diabetes Metab 12 A.D.; 3(1).
22. Levy B.I. Can angiotensin II type 2 receptors have deleterious effects in cardiovascular disease? Implications for therapeutic blockade of the renin-angiotensin system. Circulation 2004, 109(1):8-13.
23. Castro M. Placebo versus best-available-therapy control group in clinical trials for pharmacologic therapies: which is better?. Proc Am Thorac Soc 2007, 4(7):570-573.
24. Strauss M.H., Hall A. Angiotensin receptor blockers should be regarded as first-line drugs for stroke prevention in both primary and secondary prevention settings: no. Stroke 2009, 40(9):3161-3162.
25. Pitt B., Poole-Wilson P.A., Segal R., et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial-the Losartan Heart Failure Survival Study ELITE II. Lancet 2000, 355(9215):1582-1587.
26. Dickstein K., Kjekshus J. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet 2002, 360(9335):752-760.
27. Pfeffer M.A., Braunwald E., Moye L.A., et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992, 327(10):669-677.
28. Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100,000 patients in randomized trials. ACE Inhibitor Myocardial Infarction Collaborative Group. Circulation 1998, 97(22):2202-2212.
29. Yusuf S., Teo K.K., Pogue J., et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008, 358(15):1547-1559.
30. Kaul S., Diamond G.A. Good enough: a primer on the analysis and interpretation of noninferiority trials. Ann Intern Med 2006, 145(1):62-69.
31. Brugts J.J., van Vark L., Akkerhuis M., et al. Impact of renin-angiotensin system inhibitors on mortality and major cardiovascular endpoints in hypertension: a number-needed-to-treat analysis. Int J Cardiol 2015, 181:425-429.
32. Ryden L., Grant P.J., Anker S.D., et al. ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J 2013, 34(39):3035-3087.
33. Cheng J., Zhang W., Zhang X., et al. Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: a meta-analysis. JAMA Intern Med 2014, 174(5):773-785.
34. Patel A., MacMahon S., Chalmers J., et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007, 370(9590):829-840.
35. Haller H., Ito S., Izzo J.L., et al. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med 2011, 364(10):907-917.
36. Tobe S.W., Clase C.M., Gao P., et al. Cardiovascular and renal outcomes with telmisartan, ramipril, or both in people at high renal risk: results from the ONTARGET and TRANSCEND studies. Circulation 2011, 123(10):1098-1107.
37. Vejakama P., Thakkinstian A., Lertrattananon D., Ingsathit A., Ngarmukos C., Attia J. Reno-protective effects of renin-angiotensin system blockade in type 2 diabetic patients: a systematic review and network meta-analysis. Diabetologia 2012, 55(3):566-578.
38. Padwal R., Lin M., Eurich D.T. The comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in patients with diabetes. J Clin Hypertens (Greenwich) 2015, 1-7.
39. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med 1987, 316(23):1429-1435.
40. Flather M.D., Yusuf S., Kober L., et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet 2000, 355(9215):1575-1581.
41. Cohn J.N., Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001, 345(23):1667-1675.
42. Pfeffer M.A., Swedberg K., Granger C.B., et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003, 362(9386):759-766.
43. Granger B.B., Swedberg K., Ekman I., et al. Adherence to candesartan and placebo and outcomes in chronic heart failure in the CHARM programme: double-blind, randomised, controlled clinical trial. Lancet 2005, 366(9502):2005-2011.
44. Yusuf S., Sleight P., Pogue J., Bosch J., Davies R., Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000, 342(3):145-153.
45. Fox K.M. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003, 362(9386):782-788.
46. Braunwald E., Domanski M.J., Fowler S.E., et al. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med 2004, 351(20):2058-2068.
47. Dagenais G.R., Pogue J., Fox K., Simoons M.L., Yusuf S. Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials. Lancet 2006, 368(9535):581-588.
48. Yusuf S., Teo K., Anderson C., et al. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet 2008, 372(9644):1174-1183.
49. Yusuf S., Diener H.C., Sacco R.L., et al. Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med 2008, 359:1225-1237.
50. Smith S.C., Benjamin E.J., Bonow R.O., et al. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. Circulation 2011, 124(22):2458-2473.
51. Hansson L., Hedner T., Dahlof B. Prospective randomized open blinded end-point (PROBE) study. A novel design for intervention trials. Prospective Randomized Open Blinded End-Point. Blood Press 1992, 1(2):113-119.
52. Kaul S., Diamond G.A. Trial and error. How to avoid commonly encountered limitations of published clinical trials. J Am Coll Cardiol 2010, 55(5):415-427.
53. Higgins J.P., Altman D.G., Gotzsche P.C., et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011, 343:d5928.
54. Kohro T., Yamazaki T. Cardiovascular clinical trials in Japan and controversies regarding prospective randomized open-label blinded end-point design. Hypertens Res 2009, 32(2):109-114.
55. Retraction-Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality study. Lancet 2013, 382(9895):843.
56. Sawada T., Yamada H., Dahlof B., Matsubara H. Retraction of: Effects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high cardiovascular risks: KYOTO HEART Study [Eur Heart J (2009) 30:2461-2469, doi: 10.1093/eurheartj/ehp363]. Eur Heart J 2013, 30:2461-2469.